Methods for treating familial adenomatous polyposis
Provided are methods for preventing or delaying the need for surgical intervention in a patient having familial adenomatous polyposis (FAP) and an at least partially intact lower gastrointestinal tract. Also provided are methods for preventing or delaying the formation of neoplasia and/or cancer in a patient having FAP. The methods comprise administering an effective amount of a pharmaceutical therapy that comprises eflornithine and sulindac to a patient having FAP and an intact lower gastrointestinal tract.
1. A method of treating a patient having familial adenomatous polyposis (FAP), the method comprising administering to the patient a pharmaceutical therapy comprising a combined effective amount of eflornithine and sulindac, wherein the patient has an at least partially intact lower gastrointestinal tract.
2. The method of claim 1 , wherein the method delays or prevents a familial adenomatous polyposis (FAP) event and/or FAP progression in the patient.
3. The method of claim 1 , wherein the method delays FAP disease progression in the patient.
4. The method of claim 1 , wherein the method delays or prevents the need for excisional intervention.
5. The method of claim 1 , wherein the method delays or prevents the development of adenomas.
6. The method of claim 5 , wherein the adenomas are high risk adenomas.
7. The method of claim 1 , wherein the method delays polyposis progression.
8. The method of claim 7 , wherein the method delays the need for endoscopic excision or surgical resection.
9. The method of claim 1 , wherein the method prevents polyposis progression.
10. The method of claim 9 , wherein the method prevents the need for endoscopic excision or surgical resection.
11. The method of claim 1 , wherein the method delays the formation of colorectal cancer in the patient.
12. The method of claim 1 , wherein the method prevents the formation of colorectal cancer in the patient.
13. The method of claim 1 , wherein the patient has a colorectum, a retained rectum, or an ileal pouch.
14. The method of claim 1 , wherein the combined effective amount of eflornithine and sulindac comprises 750 mg/day eflornithine and 150 mg/day sulindac.
15. The method of claim 14 , wherein the eflornithine and sulindac are administered in a single formulation.
16. The method of claim 15 , wherein the single formulation comprises about 375 mg of eflornithine hydrochloride monohydrate.
17. The method of claim 15 , wherein the single formulation comprises about 288.6 mg of eflornithine in its anhydrous, free base form.
18. The method of claim 15 , wherein the single formulation comprises about 75 mg of sulindac.
19. The method of claim 15 , wherein the single formulation is in the form of a tablet.
20. The method of claim 15 , wherein the patient is administered two units of the single formulation per day.